Azurity Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AZURITY, and when can generic versions of AZURITY drugs launch?
AZURITY has thirty-three approved drugs.
There are one hundred US patents protecting AZURITY drugs. There is one tentative approval on AZURITY drugs.
There are three hundred and fifty patent family members on AZURITY drugs in forty-eight countries and forty-three supplementary protection certificates in fifteen countries.
Summary for Azurity
International Patents: | 350 |
US Patents: | 100 |
Tradenames: | 34 |
Ingredients: | 30 |
NDAs: | 33 |
Patent Litigation for Azurity: | See patent lawsuits for Azurity |
PTAB Cases with Azurity as petitioner: | See PTAB cases with Azurity as petitioner |
Drugs and US Patents for Azurity
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-001 | Dec 20, 2011 | RX | Yes | No | 9,169,238 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-005 | Apr 16, 2021 | DISCN | Yes | No | 11,160,772 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Azurity | FIRVANQ KIT | vancomycin hydrochloride | FOR SOLUTION;ORAL | 208910-002 | Jan 26, 2018 | AB | RX | Yes | Yes | 10,959,949 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-002 | Dec 13, 2011 | RX | Yes | No | 8,114,909 | ⤷ Subscribe | ⤷ Subscribe | ||||
Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | RX | Yes | Yes | 8,114,909 | ⤷ Subscribe | ⤷ Subscribe | ||||
Azurity | THYQUIDITY | levothyroxine sodium | SOLUTION;ORAL | 214047-001 | Nov 30, 2020 | RX | Yes | Yes | 9,050,307 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Azurity | TRIPTODUR KIT | triptorelin pamoate | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 208956-001 | Jun 29, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Azurity
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | 5,736,555 | ⤷ Subscribe |
Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-002 | Feb 25, 2011 | 5,736,555 | ⤷ Subscribe |
Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | 7,572,920 | ⤷ Subscribe |
Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-002 | Jan 30, 2019 | 10,130,580 | ⤷ Subscribe |
Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 5,179,189 | ⤷ Subscribe |
Azurity | NYMALIZE | nimodipine | SOLUTION;ORAL | 203340-002 | Apr 8, 2020 | 8,517,997 | ⤷ Subscribe |
Azurity | VERELAN | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 019614-001 | May 29, 1990 | 4,863,742 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Tablets | 300 mg | ➤ Subscribe | 2006-05-19 |
➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
➤ Subscribe | Extended-release Tablets | 100 mg and 200 mg | ➤ Subscribe | 2006-07-20 |
➤ Subscribe | Powder for Oral Solution | 1 mg/mL | ➤ Subscribe | 2016-06-21 |
International Patents for Azurity Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2538802 | ⤷ Subscribe |
China | 106573037 | ⤷ Subscribe |
Cyprus | 1113583 | ⤷ Subscribe |
Norway | 338275 | ⤷ Subscribe |
Norway | 20083956 | ⤷ Subscribe |
South Africa | 200309679 | ⤷ Subscribe |
South Korea | 20070017977 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Azurity Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1003503 | 05C0048 | France | ⤷ Subscribe | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
1718641 | 1290016-3 | Sweden | ⤷ Subscribe | PRODUCT NAME: AZILSARTANMEDOXOMIL OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV, INKLUDERANDE KALIUMSALT; REG. NO/DATE: EU/1/11/735/001 20111207 |
2119715 | 2018/006 | Ireland | ⤷ Subscribe | PRODUCT NAME: COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTALIDONE (EDARBYCLOR); NAT REGISTRATION NO/DATE: PA/2167/001/001-002 20170804; FIRST REGISTRATION NO/DATE: 63145 01-02 20141028 |
1718641 | 436 | Finland | ⤷ Subscribe | |
0503785 | CA 2011 00026 | Denmark | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
1718641 | PA2012004,C1718641 | Lithuania | ⤷ Subscribe | PRODUCT NAME: AZILSARTANUM MEDOXOMILUM; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/734/011, 2011 12 07, EU/1/11/735/001 - EU/1/11/735/011 20111207 |
0984957 | SPC/GB11/013 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.